The EU’s product liability framework is undergoing major change.
In Germany, a draft bill to implement the new Product Liability Directive has already been published, expected to be finalized by December 2026. It lowers the burden of proof for claimants and introduces new disclosure duties, easing consumer compensation. In parallel, mass claims are rising across Europe. Our discussion will focus on how the evolving liability regime and the growth of mass actions intersect — and whether this matters for the Life Sciences sector — highlighting key legal and strategic implications for market participants.